HIV Pre-Exposure Prophylaxis Clinical Trials in Johannesburg, Gauteng
2 recruitingJohannesburg, Gauteng, South Africa
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled78 locationsNCT07044297
Recruiting
Phase 3
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled29 locationsNCT07071623